Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin,Pravastatin and Simvastatin: Analysis of the Stellar Trial
Restricted accessOtherFirst published online February, 2005
Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin,Pravastatin and Simvastatin: Analysis of the Stellar Trial
Rosuvastatin calcium (CRESTOR®) has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C). However, healthcare providers and authorities require information on its cost-effectiveness in the treatment of dyslipidaemia.
Design
A retrospective pharmacoeconomic analysis was performed using data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. The cost-effectiveness of rosuvastatin 10-40 mg was compared with atorvastatin 10-80 mg, pravastatin 10-40 mg and both branded and generic simvastatin 10-80 mg in achieving Third Joint European Task Force LDL-C goals in patients with hypercholesterolaemia.
Methods
The analysis was conducted from the perspective of the UK National Health Service, using clinical data from the STELLAR trial and drug acquisition costs. Cost-effectiveness was compared using incremental cost-effectiveness ratios (ICERs), with sensitivity analyses applied to both efficacy and cost parameters.
Results
In terms of patients achieving goal, rosuvastatin 10 mg dominated (was more effective at equal or lower cost) atorvastatin 10 and 20 mg, pravastatin 20 and 40 mg, branded simvastatin 10-80 mg and generic simvastatin 40 and 80 mg. Where rosuvastatin 10 mg did not dominate, ICERs ranged from £36 to £162 per extra patient to goal. Rosuvastatin 20 and 40 mg were cost-effective compared with milligram-equivalent and higher doses of other branded statins. Sensitivity analyses showed that the results were robust to variations in both statin efficacy and price.
National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; final report). Circulation2002; 106: 3143–3421.
2.
Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383–1389.
3.
ShepherdJ, CobbeSM, FordI, IslesCG, LorimerAR, MacFarlanePWPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333: 1301–1307.
4.
SacksFM, PfefferMA, MoyeLA, RouleauJL, RutherfordJD, ColeTGThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335: 1001–1009.
5.
ShepherdJ. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet2002; 359: 2271–2273.
6.
DeBackerG, AmbrosioniE, Borch-JohnsenK, BrotonsC, CifkovaR, DallongevilleJEuropean guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J2003; 24: 1601–1610.
7.
PignoneM, PhillipsC, MulrowC. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ2000; 321: 983–986.
8.
TeoKK, BurtonJR. Who should receive HMG CoA reductase inhibitors?Drugs2002; 62: 1707–1715.
9.
PaolettiR, FahmyM, MahlaG, MizanJ, SouthworthH. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk2001; 8: 383–390.
10.
BrownWV, BaysHE, HassmanDR, McKenneyJ, ChitraR, HutchinsonHEfficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J2002; 144: 1036–1043.
11.
DavidsonM, MaP, SteinEA, GottoA.M.Jr, RazaA, ChitraRComparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type lla or llb hypercholesterolemia. Am J Cardiol2002; 89: 268–275.
12.
OlssonAG, IstadH, LuurilaO, OseL, StenderS, TuomilehtoJEffects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J2002; 144: 1044–1051.
13.
JonesPH, DavidsonMH, SteinEA, BaysHE, McKenneyJM, MillerEComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol2003; 92: 152–160.
14.
SchneckDW, KnoppRH, BallantyneCM, McPhersonR, ChitraRR, SimonsonSGComparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol2003; 91: 33–41.
15.
SchusterH, BarterPJ, StenderS, CheungRC, BonnetJ, MorrellJMEffects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J2004; 147: 705–712.
16.
ShepherdJ, HunninghakeDB, BarterP, McKenneyJM, HutchinsonHG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol2003; 91(Suppl. 5A): 11C–19C.
17.
ShepherdJ, HunninghakeDB, SteinEA, KasteleinJJ, HarrisS, PearsJSafety of rosuvastatin. Am J Cardiol2004; 94: 882–888.
18.
British Medical Association & Royal Pharmaceutical Society of Great Britain.British National Formulary 46.London: British Medical Association & Royal Pharmaceutical Society of Great Britain; September 2003.
19.
Great Britain Department of Health and Great Britain National Assembly for Wales.Drug tariff National Health Service, England and Wales.London: The Stationery Office (TSO); November 2003.
20.
PearsonTA, LauroraI, ChuH, KafonekS. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med2000; 160: 459–467.
21.
GrundySM, CleemanJl, MerzNB, BrewerH.B.Jr, ClarkLT, HunninghakeDBImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation2004; 110: 227–239.
22.
PalmerSJ, BradyAJ, RatcliffeAE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract2003; 57: 792–800.
23.
KongSX, CrawfordSY, GandhiSK, SeegerJD, SchumockGT, LamNPEfficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials. Clin Ther1997; 19: 778–797.
24.
DartA, JerumsG, NicholsonG, d'EmdenM, Hamilton-CraigI, TallisGA multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol1997; 80: 39–44.
25.
DavidsonM, McKenneyJ, SteinE, SchrottH, Bakker-ArkemaR, FayyadRComparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol1997; 79: 1475–1481.
Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002; 360: 7–22.
28.
EUROASPIRE II Study Group.Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J2001; 22: 554–572.
29.
JönssonB, JohannessonM, KjekshusJ, OlssonAG, PedersenTR, WedelH. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J1996; 17: 1001–1007.
30.
JohannessonM, JönssonB, KjekshusJ, OlssonAG, PedersenTR, WedelH. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med1997; 336: 332–336.
31.
HuseDM, RussellMW, MillerJD, KraemerDF, D'AgostinoRB, EllisonRCCost-effectiveness of statins. Am J Cardiol1998; 82: 1357–1363.
32.
ElliottWJ, WeirDR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm1999; 56: 1726–1732.
33.
McKenneyJM. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. Pharmacoeconomics1998; 14(Suppl. 3): 19–28.
